Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Pembrolizumab ====== Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a [[humanized antibody]] used in cancer [[immunotherapy]]. This includes treating [[melanoma]], [[lung cancer]], [[head and neck cancer]], [[Hodgkin lymphoma]], and stomach cancer. It is given by slow injection into a vein. ---- anti-[[PD-1]] drug (monoclonal antibody to PD-1 programmed cell death receptor): [[pembrolizumab]] (Keytruda) approved for advanced or unresectable melanoma not responding to other drugs ((U.S. Food and Drug Administration (FDA). FDA approves Keytruda for advanced melanoma. 2014. https://wayback.archive-it.org/7993/ 20170112023823/http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm412802.htm)). ===== Pembrolizumab for non-Small-cell lung cancer ===== [[Pembrolizumab for non-Small-cell lung cancer]]. ===== Pembrolizumab for glioblastoma ===== [[Pembrolizumab for glioblastoma]]. ===== References ===== pembrolizumab.txt Last modified: 2024/06/07 03:00by 127.0.0.1